top of page
ARDIA Full Logo .png

Targeting the Drivers of Inflammatory Skin Disease

At ARDIA, we are passionate about developing novel therapies to improve the lives of patients living with debilitating skin disorders
Our Therapeutic Approach is designed to promote cellular maturity and restore epidermal integrity

DIA-615: First-in-Class

Our proprietary topical formulation calms the cellular stress pathways responsible for chronic skin damage

Positioned For Rapid Clinical Advancement

Leveraging an established safety foundation supports efficient clinical evaluation in rare skin diseases

Rare Market Indications

Significant unmet medical need
Cutaneous Lupus Erythematosus (CLE)
Epidermolysis Bullosa Simplex (EBS)
ORPHAN DESIGNATION ELIGIBLE
Explore the Science
View Our Pipeline
Contact Us
bottom of page